Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 23;6(6):CD016183.
doi: 10.1002/14651858.CD016183.

Myosin inhibitors for treatment of hypertrophic cardiomyopathy

Samuel Quill  1   2 , Ahmad S Amin  2   3   4 , Folkert W Asselbergs  1   3   4   5 , Connie Bezzina  3   4   6 , Perry M Elliott  1   7 , Jolanda van der Velden  3   4   8 , Amand F Schmidt  1   2   4
Affiliations

Myosin inhibitors for treatment of hypertrophic cardiomyopathy

Samuel Quill et al. Cochrane Database Syst Rev. .

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: Primary objective To assess the effects of myosin inhibitors compared to usual care or placebo on exercise capacity, need for septal reduction therapy, and all-cause mortality in people with hypertrophic cardiomyopathy (HCM). Secondary objectives To assess the effects of myosin inhibitors compared to usual care or placebo in people with HCM in the following population subgroups. By demographics, such as age and sex Obstructive HCM versus non-obstructive HCM Genotype-negative and genotype-positive disease People with and without pre-existing atrial fibrillation or other types of arrhythmias.

PubMed Disclaimer

Conflict of interest statement

SQ: none.

ASA: has acted as a consultant for Bristol‐Myers Squibb.

FA: has acted as a consultant for Healthsage BV.

CRB: has acted as a consultant for Tenaya Therapeutics, and has received research funding from the Horstingstuit Foundation.

PE: has acted as a consultant for Sarepta Therapeutics Inc, BioMarin Pharmaceutical Inc, Sanofi and Genzyme US Companies, Myokardia, Novo Nordisk, Affinia Therapeutics, Pfizer, Amicus Therapeutics Inc, AstraZeneca, and Bristol‐Myers Squibb. Additionally, PE has participated on a Data And Safety Monitoring for Cytokinetics.

JVD: none.

AFS: none.

Both SQ and AFS confirm that they have no relevant financial interests to declare. They also have not been involved in myosin inhibitor studies. Similarly, neither SQ nor AFS – who are making decisions about study eligibility, data extraction, risk of bias assessment, or GRADE assessments – have been involved in the conduct, analysis, or publication of a study that could be included in the review.

Similar articles

See all similar articles

References

    1. Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. New England Journal of Medicine 2018;379(7):655-68. [DOI: 10.1056/NEJMra1710575] - DOI - PubMed
    1. Ireland CG, Ho CY. Genetic testing in hypertrophic cardiomyopathy. American Journal of Cardiology 2024;212:S4-S13. [DOI: 10.1016/j.amjcard.2023.10.032] - DOI - PubMed
    1. Alfares AA, Kelly MA, McDermott G, Funke BH, Lebo MS, Baxter SB, et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genetics in Medicine 2015;17(11):880-8. [DOI: 10.1038/gim.2014.205] - DOI - PubMed
    1. Lopes LR, Ho CY, Elliott PM. Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice. European Heart Journal 2024;45(30):2727-34. - PMC - PubMed
    1. Marvao A, McGurk KA, Zheng SL, Thanaj M, Bai W, Duan J, et al. Phenotypic expression and outcomes in individuals with rare genetic variants of hypertrophic cardiomyopathy. Journal of the American College of Cardiology 2021;78(11):1097-110. [DOI: 10.1016/j.jacc.2021.07.017] - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources